US 12,258,402 B2
Antibody specific to nectin cell adhesion molecule 4 and uses thereof
Bor-Yu Tsai, New Taipei (TW); Shin-Tsung Huang, Taipei (TW); and Wei-Ting Hsu, Taipei (TW)
Assigned to NAVI BIO-THERAPEUTICS, INC., Kaohsiung (TW)
Filed by NAVI BIO-THERAPEUTICS, INC., Kaohsiung (TW)
Filed on Jan. 12, 2023, as Appl. No. 18/153,993.
Claims priority of provisional application 63/266,711, filed on Jan. 12, 2022.
Prior Publication US 2023/0220078 A1, Jul. 13, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 47/6849 (2017.08); A61P 35/00 (2018.01); A61K 39/00 (2013.01)] 14 Claims
 
1. An antibody or antigen-binding fragment thereof specific for an epitope on nectin cell adhesion molecule 4 (nectin-4) or a fragment thereof, which comprises complementarity determining regions (CDRs) of a heavy chain variable region and CDRs of a light chain variable region, wherein the CDRs of the heavy chain variable region comprises CDRH1, CDRH2 and CDRH3 regions, and the CDRs of the light chain variable region comprises CDRL1, CDRL2 and CDRL3 regions, and wherein:
the CDRH1 region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 to 6; the CDRH2 region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8 to 12; and the CDRH3 region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 14 to 18; and
the CDRL1 region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 20 to 24; the CDRL2 region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 26 to 30; and the CDRL3 region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 32 to 36.